2021 Kentucky Harm Reduction Summit

2021 Kentucky Harm Reduction Summit - A Statewide Collaborative Approach to Improving Care for Pregnant People Affected by Opioid Use in Massachusetts

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • CPE: 1.25
    • Other: 1.25
    • CNE: 1.25
  • Cost: Free
  • Release: Nov 8, 2021
  • Expires: Nov 7, 2024
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • Average User Rating:
    ( Ratings)
This content was recorded from the live event on August 11th and 12th, 2021. If you attended and claimed credit, please do not complete this release. 

Faculty

Ronald  E.  Iverson, Jr. Ronald E. Iverson, Jr., MD, MPH
Director, Quality and Safety
Director, Credentialing and Privileging
Assistant Professor
Vice Chair of Obstetrics
Department of OBGYN
Boston University
Boston, Massachusetts

Kali Vitek Kali Vitek, MPH
Project Management Specialist
Massachusetts Perinatal-Neonatal Quality Improvement Network
Boston Medical Center
Boston, Massachusetts

Needs Statement

Healthcare teams lack awareness and knowledge about harm reduction services including: 1) prevention and response efforts, 2) available resources, 3) promising practices, 4) disease testing and prevention, 5) addiction and recovery services, 6) local and state partnerships, and 7) the current status of the drug overdose epidemic.

Target Audience

Physicians, Nurses, Pharmacists, Registered Sanitarians

 

 

 

 

Objectives

Upon completing this activity, participants will be able to:

  • Explain why our Perinatal Quality Collaborative in Massachusetts focused on OUD for our first AIM project.
  • Discuss key steps that our PQC has taken with our collaborating hospitals.
  • View appropriate statewide measurements related to caring for people with OUD and their newborns.

Accreditation

Joint Accreditation Logo

 

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA credit: 
This live is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC credit:
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hour(s).

ACPE credit:
This knowledge-based activity will award 1.25 contact hour (.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

RS/REHS credit:
This activity has been approved for a total of 1.25 CEU Hours. When claiming credit, please choose 'Other' credit type

Other/Participation:
UK Healthcare CECentral certifies this activity for 1.25 hours of participation.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This activity is jointly provided by the Kentucky Injury Prevention and Research Center (KIPRC) at the University of Kentucky, Kentucky Cabinet for Health and Family Services, Kentucky Income Reinvestment Program (KIRP), and Kentucky Department of Public Health (KDPH).

In collaboration with Kentucky Aids Education Training Center (KY AETC), Barren River District Health Department, Kentucky Mobile Harm Reduction, Kentucky Opioid Response Effort, and Kentucky Public Health.

The 2021 Harm Reduction Summit is supported by Cooperative Agreement Number 6 NU17CE924971 funded by the Centers for Disease Control and
Prevention, and awarded to the University of Kentucky Research Foundation and the Kentucky Injury Prevention and Research Center. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.